Wockhardt signaled a strategic inflection from (1) liquidity survival (FY18–FY23) to (2) profitability repair (last ~3 years) to now (3) growth scaling, anchored by Zaynich—“first Indian company to have an Indian research product approved with the US FDA, Zaynich.”
9
1August 31, 2026 1.5K 1
